Biocartis receives EUR 2.5m strategic grant from flemish government to support manufacturing capacity expansion

Biocartis, an innovative molecular diagnostics company, announced that it has received a EUR 2.5m grant from the Flemish Agency for Innovation & Entrepreneurship under its Strategic Transformation Support (‘STS’) program.

Biocartis has received the STS grant in order to support the manufacturing capacity expansion for its Idylla diagnostics tests as well as to support the training and education of existing and new personnel necessary to operate a new manufacturing line that will be installed in Mechelen.

Ewoud Welten, CFO of Biocartis, commented: “Biocartis is grateful for the financial support it has received from the Flemish government. This is demonstrating the continued commitment of the government to invest in innovation and growth in the Flemish region. The STS grant that we received will further enable us in realizing the required expansion of our manufacturing capacity. However and equally important, it will also support our ongoing investment in dedicated people, who in the end are the ones that drive the availability of our high precision and cost effective solutions to customers and patients.”

Biocartis EUR yole

Minister Muyters, the Flemish Minister of Work, Economy, Innovation and Sports, commented: “The STS program supports projects that make a significant contribution to the strengthening of the economic development in Flanders. The manufacturing expansion project that is ongoing at Biocartis is an excellent example of this. We as government are pleased to be in the position to further stimulate smart and disruptive innovation in Flanders, as showcased by Biocartis.